429
Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.
 prevention of chemotherapy-induced nausea and vomiting: Effect; Aprepitant: Treatment; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Treatment; Aprepitant: Treatment.Drug; corticosteroid: Treatment.Drug; 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Treatment.Drug; Aprepitant: Combination.Drug; corticosteroid: Combination.Drug; 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 prevention of chemotherapy-induced nausea and vomiting: Effect; Aprepitant: Treatment; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Treatment; Aprepitant: Treatment.Drug; corticosteroid: Treatment.Drug; 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Treatment.Drug; Aprepitant: Combination.Drug; corticosteroid: Combination.Drug; 5-hydroxytryptamine(3) (5-HT(3)) antagonist: Combination.Drug